Thermo Fisher Scientific Human G-CSF Recombinant Protein

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Control (Ctrl)

Assay-dependent

-

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

Amino acids Thr31- Pro204 containing an N-terminal His-tag

Tag

His-tag

Molecular weight

23.19 kDa

Class

Recombinant

Type

Protein

Purity

>95%, by SDS-PAGE under reducing conditions

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.1 mg/mL

Purification

purified

Storage buffer

20mM tris HCl, pH 8, with 50% glycerol

Contains

no preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

Product Specific Information

This product contains purified recombinant human GCSF protein with an N-terminal hexahistidine tag.

This product may be used as a positive control in many immunological assays.

Target Information

G-CSF (Granulocyte colony stimulating factor) is a naturally occurring cytokine that stimulates the production and antibacterial function of neutrophils and monocytes. Human G-CSF is an 18.8 kDa protein containing 175 amino acid residues, and a soluble isoform of the G-CSF receptor has been described. The pleotropic cytokine is produced by activated monocytes, macrophages, endothelial cells, fibroblasts, astrocytes, osteoblasts and bone marrow cells. G-CSF has been shown to have specific effects on the proliferation, differentiation and activation of hematopoietic cells. G-CSF is also expressed by various transformed cells such as carcinoma cells and myeloblastic leukemia cells. G-CSF is encoded by two distinct DNA sequences, resulting in a full size, high activity and a shorter, low activity isoform of G-CSF. G-CSF is highly conserved among species and has been shown to exert its biological functions through interaction with its receptor expressed on the surface of hematopoietic progenitors, neutrophilic granulocytes and certain carcinoma cell lines. Clinical use of G-CSF has been approved for several therapeutic applications, treatment of neonatal infections, therapy of acute myocardial infarction, granulocyte transfusion in patients with neutropenia, in severe infections and sepsis, therapy in chronic autoimmune neutropenia, treatment of acute myeloid leukemias, Sweet`s syndrome and AIDS. Further, G-CSF has been shown to be a marker protein for different carcinomas such as bladder cancer and dysfunction of the protein has been linked to Kostmann Syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.